Integrative Oncology Outcomes Study in Breast Cancer (IO-OS-BC)

Study Description

Go to 

Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Brief Summary:

This NIH-NCCAM funded epidemiologic research is being conducted as an observational prospective case-control study of the use of Complementary and Alternative Medicine (CAM) and Integrated Oncology (IO) and their effects on breast cancer patients in community settings.

Hypothesis: IO services improve patients' quality of life and decrease cancer recurrence rates in breast cancer patients as compared to women with similar disease states and prognoses who do not receive IO care, and may or may not use CAM treatment on their own.

Condition or disease
Breast Cancer

Study Design

Go to 

Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Study Type :	Observational
Actual Enrollment :	750 participants
Observational Model:	Case-Control
Time Perspective:	Prospective
Official Title:	Breast Cancer Integrative Oncology: Prospective Matched Controlled Outcomes Study
Study Start Date :	August 2010
Actual Primary Completion Date :	December 31, 2017
Actual Study Completion Date :	December 31, 2017

Groups and Cohorts

Go to 

Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Group/Cohort
IO Clinic Breast Cancer Patients; Includes patients who are receiving care for their breast cancer at participating Seattle area IO clinics.
CSS Match-Control Patients; For each IO clinic patient, an average of two (up to four) matched comparison cases will be recruited from the Washington State Cancer Surveillance System (CSS). Matched comparison cases from CSS will be identified by CSS and confirmed by the FHCRC investigator.

Outcome Measures

Go to 

Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :

1. Aim 1: Describe treatments received by breast cancer patients receiving physician level practitioner IO care and the cost of IO care. [ Time Frame: Baseline, 6, 12, 24, 36, 48, and 60 months post study enrollment. ]
   Will also describe how long after diagnosis women with breast cancer seek IO care and differences in IO care prescriptions associated with when, in a woman's course of treatment, she seeks care. This patient cohort will consist of all female patients with breast cancer seeking IO clinic care. Our analyses will describe how long after diagnosis women with breast cancer seek IO care and describe differences in IO care prescriptions associated with when, in a woman's course of treatment, she seeks care.
2. Aim 2: Compare health-related quality of life (HRQOL) experienced by a group of breast cancer patients receiving IO care with HRQOL of a group of matched comparison women. [ Time Frame: 6-60 months post-enrollment ]
   Comparison will be between breast cancer patients living in the same geographic area with similar prognostic characteristics (age, stage of cancer at diagnosis, estrogen receptor/ progesterone receptor (ER/PR) status, race, ethnicity, and marital status) at the time of their initial diagnosis with breast cancer who did not receive IO care. We will identify an average of three (up to four each) matched controls for each eligible IO clinic cancer patient from the Western Washington CSS database and to invite them to enroll in the outcomes study.

Secondary Outcome Measures :

1. Aim 3: Collect pilot data on survival, comorbidities, and abnormal laboratory values. [ Time Frame: 6-60 months post-enrollment ]
   Collect pilot data on disease-free, progression free, and overall survival, as well as comorbidities and abnormal laboratory values at 6 months post-enrollment for all Cohort 1 and Cohort 2. We will collect data at 1 year post-enrollment and then yearly on disease-free, progression free, and overall survival, as well as comorbidities for as long as funding is available in a nested cohort of IO breast cancer patients (Cohort 1A) and their matched comparison group who did not receive care at any of the IO clinical sites (Cohort 2).
2. Aim 4: Describe and compare CAM treatments [ Time Frame: Baseline, 6, 12, 24, 48, and 60 months ]
   Describe and compare the frequency of use of a variety of CAM treatments used by breast cancer patients who do (Cohort 1A) and do not (Cohorts 2A and 2B) receive IO care from an IO specialist.
3. Aim 5: Compare the HRQOL of women who self-prescribe CAM with those who do not [ Time Frame: Baseline and 6, 12, 24, 36, 48 and 60 months post-enrollment ]
   To compare baseline and changes in HRQOL in breast cancer patients who self-prescribe CAM (Cohort 2B) matched with comparison women who do not use CAM (Cohort 2A).

Eligibility Criteria

Go to 

Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Ages Eligible for Study:	18 Years and older (Adult, Senior)
Sexes Eligible for Study:	Female
Accepts Healthy Volunteers:	No
Sampling Method:	Non-Probability Sample

Study Population

Eligible participants for the study will include patients who are receiving care for their cancer at participating Seattle area IO clinics. An average of two (up to four) matched comparison controls will be recruited from the Washington State CSS.

All breast cancer patients seeking care at the participating IO clinics who meet inclusion/exclusion criteria are eligible to participate in this study. Matched comparison cases from CSS will be identified by CSS and confirmed by the FHCRC investigator.

Criteria

The patients enrolled into the study will include patients who meet the following criteria:

Cohort 1: IO clinic breast cancer patients

1. Confirmed breast cancer of primary breast cancer with ICD9 code of 174.x, 233.0 or V10.3
2. Female
3. ≥18 years of age
4. Can provide signed informed consent
5. 1st IO clinic visit ≤3 months prior to enrollment
6. Can read and understand the questionnaires

Cohort 1A: Sub-cohort of IO clinic patients (cases) who meet the following additional criteria and for whom matched controls have been found from the CSS database.

1. ICD9 code of 174.x or 233.0
2. Primary ductal or lobular breast cancer diagnosis ≤2 years prior to 1st IO clinic visit
3. Minimum of two IO clinic visits within 7 months
4. Provided Baseline Questionnaire

Cohort 2: Matched controls from CSS database for Cohort 1A patients

1. Confirmed breast cancer
2. Female
3. ≥ 18 years of age
4. Can provide informed consent

Contacts and Locations

Go to 

Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Locations

United States, Washington
Red Cedar Wellness Center
Bellevue, Washington, United States, 98004
Bastyr Integrative Oncology Research Center
Kenmore, Washington, United States, 98028
Seattle Integrative Oncology at Providence Integrative Cancer Care
Lacey, Washington, United States, 98503
Seattle Cancer Treatment & Wellness Center
Renton, Washington, United States, 98057
Seattle Integrative Oncology at Institute of Complementary Medicine
Seattle, Washington, United States, 98122
Tree of Health Integrative Medicine
Woodinville, Washington, United States, 98072

Sponsors and Collaborators

Bastyr University

Fred Hutchinson Cancer Research Center

National Institutes of Health (NIH)

National Center for Complementary and Integrative Health (NCCIH)

Lotte & John Hecht Memorial Foundation

Investigators

Principal Investigator:	Leanna J. Standish, ND, PhD, FABNO	Bastyr University
Principal Investigator:	M. Robyn Andersen, PhD, MPH	Fred Hutchinson Cancer Research Center

More Information

Go to 

Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Responsible Party:	Bastyr University
ClinicalTrials.gov Identifier:	NCT01366248 History of Changes
Other Study ID Numbers:	09E-1237-01; 1R01AT005873 ( U.S. NIH Grant/Contract )
First Posted:	June 6, 2011
Last Update Posted:	March 22, 2018
Last Verified:	March 2018

Additional relevant MeSH terms:

Breast Neoplasms; Neoplasms by Site; Neoplasms; Breast Diseases; Skin Diseases